Novartis Eyes China Community Hospital Market
This article was originally published in PharmAsia News
Executive SummaryChina's health care reform which aims to maintain public health service is set to impact pharmaceutical MNCs. Foreign corporations are looking at community hospitals as a potential market, and Novartis has established a special institution that collaborates with community hospitals. The head of Novartis China believes local pharmaceutical companies will benefit more than MNCs from the reform, but the latter can still participate in basic health care with their generic drugs. China's immunity program expansion also brings business opportunities. Novartis is discussing with China National Biotec Group, China's key state vaccine manufacturer, on possible cooperation. (Click here for more - Chinese Language)
You may also be interested in...
An experienced hand at M&A, Ajay Piramal has done it again – this time selling Decision Resources Group to Clarivate Analytics for $950m. Apart from $900m in cash, Piramal Enterprises will get a stake in Clarivate while the latter expects the acquisition to be earnings-accretive in 2020.
San Francisco-based digital health start-up Steady Health has launched the first "virtual" full-service diabetes clinic for patients in California. See what Henrik Berggren, CEO and founder of Steady Health, said about it here.
The first phase of a major trade agreement just signed by the US and China obliges the latter to implement a system linking pharma patent enforcement to marketing authorization procedures as well as to offer patent-term extensions.